BioPortfolio - MediGene AG - Profile
Medigene AG (NMarkt: MDG) is a publicly quoted German biopharmaceutical company ... to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir. ...
http://www.bioportfolio.com/biocorporate/6855-MediGene+AG.pd...
|
Technology Evaluation: Anticancer gene therapy, MediGene Susmita Hunt
using one alone (www.medigene.de). 393376. MediGene AG: MediGene starts phase II clinical trial for. its cardiac lead product Etomoxir to treat congestive ...
http://www.biomedcentral.com/content/pdf/cd-425171.pdf...
|
BioPortfolio - MediGene AG
MediGene AG - Entry on Bioportfolio's Biocorporate Database. ... therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir.
...
http://www.bioportfolio.com/biocorporate/6855-MediGene_AG.ht...
|
Evotec / News & Events
MediGene AG (NMarkt: MDG) and EVOTEC BioSystems AG (Evotec OAI) (NMarkt: EVT) ... into clinical development following our product candidate Etomoxir." ...
http://www.evotec.com/en/news_events/news_article.aspx?news_...
|
BioPortfolio - MediGene AG - Profile
View the current MediGene AG Page on BioPortfolio.com ... A new therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir.
...
http://www.bioportfolio.com/biocorporate/26247-MediGene%2525...
|
Patent alert
No synthetic or physicochemical data are. presented. The specified compound, etomoxir (a CPT-1. inhibitor; MediGene AG), is the only compound specifically
...
http://www.biomedcentral.com/content/pdf/cd-417734.pdf...
|
Evotec / News & Events
Another cardiac drug candidate of MediGene, Etomoxir for the treatment of ... MediGene AG is a publicly quoted (Nemax50), internationally orientated ...
http://www.evotec.com/en/news_events/news_article.aspx?news_...
|
A new therapeutic approach to treat psoriasis by i...[Br J ...
Medigene AG, Lochhamerstrasse 11, 82152 Martinsried, Germany. ... Etomoxir was able to block CPT-1 activity in skin, implying that this antagonist may have ...
http://www.ncbi.nlm.nih.gov/pubmed/16225603...
|
Evotec / News & Events / Pressemitteilungen
Zu den Herzmedikamenten der MediGene AG gehört bereits der Wirkstoff Etomoxir, der derzeit in der klinischen Phase 2 zur Behandlung der chronischen ...
http://www.evotec.com/de/news_events/news_article.aspx?news_...
|
Patent alert
physicochemical data are presented. The specified. compound, etomoxir (a CPT-1 inhibitor; MediGene AG), is. the only compound specifically claimed for use. ...
http://www.biomedcentral.com/content/pdf/cd-418382.pdf...
|
